KUALA LUMPUR, June 5 (Xinhua) Malaysian regulators have approved clinical trials of the inactivated COVID-19 vaccine developed by Shenzhen Kangtai Biological
Trending
Pneumonia Vaccines Market
radoffMay 23, 2021
The report on the Pneumonia Vaccines Market published by Stratview Research focuses on current trends, dynamics, insights and also predicts the market condition and its future during the forecast period of 2020 – 2027. The report provides in-depth insights into the market dynamics to enable informed business decision-making and growth strategy making based on the opportunities present in the market. The report is segmented by Application and Region and also covers the COVID-19 impact on the market.
Pneumonia Vaccines Market is likely to witness an impressive CAGR of 5.0% during the forecast period. Growing prevalence of chronic diseases such as chronic obstructive pulmonary disease, diabetes mellitus and chronic heart disease, pneumococcal contamination within the population, introduction of novel pneumococcal vaccines, increasing support of government in creating awareness about pneumonia immunization programs are some of
China approves one more inactivated COVID-19 vaccine for emergency use - China News sina.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sina.com Daily Mail and Mail on Sunday newspapers.
China approves one more inactivated COVID-19 vaccine for emergency use
Xinhua
15 May 2021, 16:18 GMT+10
GUANGZHOU, May 15 (Xinhua) China has approved one more inactivated COVID-19 vaccine for emergency use, according to a recent announcement. Shenzhen Kangtai Biological Products Co., Ltd., the developer of the vaccine, said on Friday that the vaccine it developed has started related work for Phase III clinical trial. The vaccine reported no adverse events with an intensity of grade 3 or above in the first two phases of its clinical trials, according to the company s research submitted to MedRxiv, a web portal distributing preprints about health sciences. A grade 3 adverse event refers to side effects that are severe or medically significant but not immediately life-threatening, according to the Common Terminology Criteria for Adverse Events.